dr. lucia masarova discusses indirect comparison of pacritinib and momelotinib in myelofibrosis
Published 9 months ago • 180 plays • Length 7:40Download video MP4
Download video MP3
Similar videos
-
1:44
myelofibrosis therapies in clinical trials | bet inhibitors
-
2:12
inese maurina fh parsirdi latvia
-
1:31
plasma ceramides: ideal candidates for testing
-
4:13
dr roy fleischmann: ‘long-term safety of sarilumab in rheumatoid arthritis'
-
2:37
allo-sct in older patients with mds: selection, donors, and timing
-
8:57
my prognosis with mixed connective tissue disease and polymyositis
-
5:26
myelofibrosis explained: what you need to know
-
5:40
countries with most number of nobel prize winners | number of nobel laureates per country
-
37:51
flurry of great news, pfizer, at-home test, long-lasting immunity
-
0:30
la jolla scientist awarded first nobel prize of the year
-
9:27
telazoparib vs physicians choice for patients with mbrca1 breast cancern
-
0:16
who is more at risk of osteoporosis?
-
1:03
why is it important for psoriasis patients to demand the best care possible?
-
13:25
comparing vaccine efficacy against hospitalization (moderna, pfizer-biontech, janssen)
-
0:30
nobel prize in physiology or medicine awarded to david julius and ardem patapoutian
-
2:13
meet christopher plastaras, md
-
1:27
bc expands use of biosimilars
-
0:52
how does multiple myeloma affect patients and what treatments are available? – professor moreau
-
2:00
cost-effectiveness of mm treatment
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma